Get Started with Your Free Care Kit

Search

Clinical Trials

Trial Name

Category

Targeted Therapy

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Beyond First Line Therapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Beyond First Line Therapy

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Beyond First Line Therapy

ICP-CL-00303

Beyond First Line Therapy

Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Beyond First Line Therapy

A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients with Advanced Biliary Tract Cancer (BTC)

First Line Therapy

PROOF Trial: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Beyond First Line Therapy

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Targeted Therapy

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3

Beyond First Line Therapy

Safety and Tolerability of TNG462 in Patients with MTAP-deleted Solid Tumors

1 2